Congratulations to Project PROTECT, recently honored with the 2025 EDSA Catalyst Award for Outstanding Industry Collaboration from the End Drug Shortages Alliance. This award honors a multi-stakeholder partnership that has measurably improved drug access and strengthened supply resilience through cooperation, transparency, and innovation.
This award is especially meaningful because it reflects what Project PROTECT was built on from the very beginning: collaboration, ingenuity, and a shared commitment to protecting patients from essential medicine shortages. Together, Angels for Change, STAQ Pharma, and the Children’s Hospital Association designed and launched a model that brings hospitals, advocacy groups, manufacturers, and supply chain experts around one table to strengthen the stability of the drug supply chain.
The End Drug Shortages Alliance (EDSA), co-founded by Angels for Change and Vizient, has grown to more than 100 members across the healthcare supply chain. The article highlights how this expanding organization is advancing transparency, data-sharing and coordinated action to strengthen access to essential medicines. Recent progress includes a pilot with children’s hospitals and distributors focused on improving visibility for critical pediatric oncology drugs. The alliance’s continued growth reflects a shared commitment to building a more resilient, patient-centered supply chain.
Angels for Change Statement Included in Congressional Hearing on Strengthening the U.S. Health Care Supply Chain
Last month, the House Energy & Commerce Health Subcommittee held a critical hearing titled: “Made in America: Strengthening Domestic Manufacturing and Our Health Care Supply Chain.”
Angels for Change submitted a formal statement for the record—bringing the voice of the patient directly to policymakers.
New Legislation Takes Aim at Drug Shortages—Angels for Change Recognized in MAPS Act Launch
Angels for Change is officially recognized in the introduction of the bipartisan Mapping America’s Pharmaceutical Supply (MAPS) Act, a groundbreaking bill introduced by Representatives Doris Matsui (D-CA) and Dan Crenshaw (R-TX). This legislation directly addresses vulnerabilities in the drug supply chain by requiring greater transparency, mapping critical drug components, and identifying potential risks before they impact patient care
